Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CM
The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) ahead of a potential regulatory submission for the agent.
Presented during a hot line session at the European Society of Cardiology (ESC) Congress 2023, results of the trial suggest the acoramidis cohort experienced an 81% survival rate at 30 months, with additional analysis suggesting use of acoramidis was associated with a 30% reduction in risk of cardiovascular death relative to placebo therapy.1
myBinderRelated Content
-
Stress Management Following hATTR Amyloidosis DiagnosisLiving with hATTR amyloidosis can cause ...
-
Cardiac Amyloidosis – What Is Amyloid and How Does It Affect the Heart?https://www.youtube.com/watch?v=o6u-nETE...
-
Chafic Karam, MDDr. Chafic Karam is a Neurologist at the...
-
Virtual Meeting – Amyloidosis Support Groups – Saturday, July 15, 2023Date & Time Saturday, July 15, 2023...
-
Systemic Amyloidosis From A (AA) to T (ATTR): A ReviewSystemic amyloidosis is a rare protein m...
-
Avoiding Misdiagnosis: Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Amyloidosis...Background: Transthyretin amyloidosis (...
-
Philadelphia — Amyloidosis Support Groups Meeting — LIVE — Saturday, April 20, 2024When: Saturday, April 20, 2024 AL wi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
